Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.36 |
| ▸ | PREP | P48147 | 8/20 | 0.36 |
| ▸ | ACE | P12821 | 2/20 | 0.35 |
| ▸ | CTNNB1 | P35222 | 3/20 | 0.32 |
| ▸ | TCF7L2 | Q9NQB0 | 3/20 | 0.32 |
| ▸ | F7 | P08709 | 1/20 | 0.32 |
| ▸ | F3 | P13726 | 1/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 2/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31486338 | 0.95 | PREP (0.36) | RPS6KB1PREPACEF7F3 | |
| SCHEMBL31486419 | 0.88 | F7 (0.41) | RPS6KB1PREPACECTNNB1TCF7L2 | |
| SCHEMBL31486352 | 0.85 | RPS6KB1 (0.37) | RPS6KB1PREPACEF7F3 | |
| SCHEMBL31486244 | 0.82 | MET (0.37) | RPS6KB1PREPACEF7F3 | |
| SCHEMBL31486440 | 0.82 | PREP (0.36) | RPS6KB1PREPACEF7F3 | |
| SCHEMBL31486191 | 0.81 | PREP (0.36) | RPS6KB1PREPACEF7F3 | |
| SCHEMBL31486238 | 0.81 | F7 (0.43) | PREPACEF7F3 | |
| SCHEMBL31486537 | 0.80 | RPS6KB1 (0.39) | RPS6KB1PREPACE | |
| SCHEMBL31486546 | 0.80 | RPS6KB1 (0.39) | RPS6KB1PREP | |
| SCHEMBL31486497 | 0.79 | PREP (0.33) | RPS6KB1PREPACEF7F3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122225-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-04-17 | — | — | US | disclosed |
| WO-2025076476-A2 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122225-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, SPINT2, SERPINB1 | RPS6KB1 2675/4885PREP 140/4885ACE 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.